1-(4-bromophenyl)-5-(1-tert-butylpyrrol-3-yl)-4-pyridin-2-ylimidazolidine-2-thione
C22H23BrN4S — CID 133182697
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-(4-bromophenyl)-5-(1-tert-butylpyrrol-3-yl)-4-pyridin-2-ylimidazolidine-2-thione
1-(4-bromophenyl)-5-(1-tert-butylpyrrol-3-yl)-4-pyridin-2-ylimidazolidine-2-thione (PubChem CID 133182697) has the molecular formula C22H23BrN4S and a molecular weight of 455.43 g/mol. Its IUPAC name is 1-(4-bromophenyl)-5-(1-tert-butylpyrrol-3-yl)-4-pyridin-2-ylimidazolidine-2-thione.
Molecular Properties
| Compound Name | 1-(4-bromophenyl)-5-(1-tert-butylpyrrol-3-yl)-4-pyridin-2-ylimidazolidine-2-thione |
|---|---|
| PubChem CID | 133182697 |
| Molecular Formula | C22H23BrN4S |
| Molecular Weight | 455.43 g/mol |
| Exact Mass | 454.08 |
| IUPAC Name | 1-(4-bromophenyl)-5-(1-tert-butylpyrrol-3-yl)-4-pyridin-2-ylimidazolidine-2-thione |
| SMILES | CC(C)(C)n1ccc(C2C(c3ccccn3)NC(=S)N2c2ccc(Br)cc2)c1 |
| InChI | InChI=1S/C22H23BrN4S/c1-22(2,3)26-13-11-15(14-26)20-19(18-6-4-5-12-24-18)25-21(28)27(20)17-9-7-16(23)8-10-17/h4-14,19-20H,1-3H3,(H,25,28) |
| InChIKey | RKRLIIRBCQOBCP-UHFFFAOYSA-N |
| XLogP | 5.58 |
| TPSA | 33.09 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 455.43 |
| LogP ≤ 5 | 5.58 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 3 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Thiocarbonyl_group', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 133182697 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.